Diabetes in cats: SGLT2 inhibitor (velagliflozin or bexagliflozin) vs insulin-based care — LIKELY

In diabetic cats (naive or insulin-treated), does an SGLT2 inhibitor (velagliflozin or bexagliflozin) vs insulin-based care achieve glycaemic control — and at what ketoacidosis cost?

Shelf #225 · gate-verified and approved by the developer

LIKELY: An SGLT2 inhibitor achieves glycaemic control comparable to insulin in diabetic cats — at a ketoacidosis cost insulin does not carry in these records. The one genuinely controlled comparison is Niessen 2024, a prospective randomised (open-label) noninferiority field trial: treatment success at day 45 was 29/54 (54%) on once-daily velagliflozin vs 26/62 (42%) on twice-daily Caninsulin, meeting noninferiority, and diabetic ketoacidosis occurred in 4/61 (7%) on velagliflozin vs 0/66 on insulin. The large open-label field studies agree on control and on cost: in SENSATION (Behrend 2024; 252 cats on velagliflozin alone), median blood glucose fell from 436 mg/dL at screening to 125 mg/dL at day 180 and 81% of remaining cats were in reference range, while ketoacidosis occurred in 18/252 (7.1%) — 5.1% (11/214) in insulin-naïve cats vs 18.4% (7/38) in previously insulin-treated cats, with 77.8% of episodes euglycaemic and most in the first 14 days. For bexagliflozin (Hadd 2023; 84 newly diagnosed, previously untreated cats, historically controlled), 68/81 evaluable cats (84.0%) were treatment successes at day 56, and euglycaemic ketoacidosis was diagnosed in 3 cats and presumed in a fourth. The stamp is LIKELY, not PROBABLE: only velagliflozin has a randomised comparison, that trial was open label, and bexagliflozin's figures are uncontrolled. Drafted Nov 10, 2026 (VetMed build, topic #225); all figures from abstracts fetched and verified at drafting.

Niessen 2024: velagliflozin was noninferior to insulin for treatment success at day 45 (54% vs 42%) — with diabetic ketoacidosis in 7% vs 0%

Randomized Controlled Trial, Veterinary (record's publication type); prospective, randomised, positive-controlled, open-label noninferiority field trial

Who: Cats: client-owned diabetic cats (127 in the safety assessment; 116 in the efficacy assessment) in a prospective field trial, randomised to once-daily oral velagliflozin 1 mg/kg or twice-daily titrated Caninsulin injections (positive control); treatment success on day 45 required improvement in at least one clinical and at least one glycaemic variable (noninferiority margin Δ: 15%).

Result: On day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority (difference −11.8%; upper 1-sided 97.5% confidence interval, −∞ to 6.3%). By day 91, quality of life, polyuria and polydipsia had improved in 81%, 54% and 61% of velagliflozin cats; on blood glucose curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin), and serum fructosamine was <450 µmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin). Velagliflozin's most frequent adverse events were loose feces/diarrhea (23/61, 38%), positive urine culture (19/61, 31%) and nonclinical hypoglycemia (BG <63 mg/dL; 8/61, 13%); Caninsulin's were clinical and nonclinical hypoglycemia (35/66, 53%), positive urine culture (18/66, 27%) and loose feces/diarrhea (10/66, 15%). Diabetic ketoacidosis occurred in 4/61 (7%; velagliflozin) and 0/66 (Caninsulin).

Watch out: This trial was open label — neither owners nor investigators were blinded, as the record states — so the design class is randomised but not blinded. The comparator is one specific insulin (Caninsulin) titrated in a field setting, and 'treatment success' is a composite requiring improvement in only one clinical and one glycaemic variable. The ketoacidosis contrast (7% vs 0%) is the price printed on the same record as the noninferiority result and must travel with it.

Niessen SJM, Kooistra HS, Forcada Y, Bjørnvad CR, Albrecht B, Roessner F, Herberich E, Kroh C. Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats. J Vet Intern Med. 2024;38(4):2099-2119. PMID: 38884190. Registry ID: none in the record. MeSH: Animals · Cats · Female · Male · Administration, Oral · Blood Glucose · Cat Diseases · Diabetes Mellitus · Drug Administration Schedule · Hypoglycemic Agents · Insulin · Prospective Studies · Sodium-Glucose Transporter 2 Inhibitors

Behrend 2024 (SENSATION): velagliflozin alone improved glycaemia over 180 days in 252 diabetic cats; ketoacidosis in 7.1%, mostly euglycaemic and mostly in the first 14 days

Prospective, baseline-controlled, open-label clinical field trial (the SENSATION study) — no concurrent control group

Who: Cats: 252 client-owned diabetic cats receiving at least two doses of once-daily oral velagliflozin solution as sole therapy — 214 (85%) insulin-naïve and 38 (15%) previously insulin-treated — followed on days 0, 3, 7, 30, 60, 120 and 180 in a prospective field trial.

Result: Screening blood glucose was a median 436 mg/dL (range 272 to 676); single post-dose BG was 153 mg/dL on day 30, 134 on day 60, 128 on day 120 and 125 mg/dL on day 180. Screening fructosamine was 538 µmol/L (375 to 794), falling to 310, 286, 269 and 263 µmol/L on the same days. At day 180, 81% of the 158 cats remaining had BG and/or fructosamine within reference ranges, and 88.6% (124/140) and 87.7% (121/138) showed improvement in polyuria and polydipsia. Ketonuria developed in 35 cats (13.9%), including 18 (7.1%) with ketoacidosis; ketoacidosis was less common in naïve cats (11/214, 5.1%) than in previously insulin-treated cats (7/38, 18.4%); at diagnosis 14/18 (77.8%) of ketoacidotic cats were euglycemic (BG < 250 mg/dL), and 30/35 (85.7%) ketosis/ketoacidosis episodes occurred within the first 14 days. No clinical hypoglycemia occurred.

Watch out: Baseline-controlled and open-label with no concurrent insulin or placebo arm — the improvements are before-and-after in the same cats, so this card supports the randomised Niessen trial rather than carrying the claim alone. Only 158 of 252 cats remained at day 180, and previously insulin-treated cats were less likely to complete the trial, so the day-180 figures describe completers. The euglycaemic presentation (77.8% with BG < 250 mg/dL) means ketoacidosis on this drug cannot be screened for by glucose alone.

Behrend EN, Ward CR, Chukwu V, Cook AK, Kroh C, Lathan P, May J, Schermerhorn T, Scott-Moncrieff JC, Voth R. Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study. J Am Vet Med Assoc. 2024;262(10):1343-1353. PMID: 39142336. Registry ID: none in the record. MeSH: Animals · Cats · Cat Diseases · Female · Male · Hypoglycemic Agents · Sodium-Glucose Transporter 2 Inhibitors · Diabetes Mellitus · Glucosides · Blood Glucose · Administration, Oral · Prospective Studies

Hadd 2023: bexagliflozin monotherapy succeeded in 84.0% of newly diagnosed diabetic cats at day 56 — euglycaemic ketoacidosis diagnosed in 3 cats and presumed in a fourth

Historically controlled prospective open-label clinical trial (record's own design wording)

Who: Cats: 84 client-owned cats newly diagnosed with diabetes mellitus and previously untreated, dosed orally with bexagliflozin 15 mg once daily for 56 days, with a 124-day extension for safety and durability; the primary endpoint was the proportion with decreased hyperglycemia and improved clinical signs of hyperglycemia at day 56.

Result: Of 84 enrolled cats, 81 were evaluable on day 56 and 68 (84.0%) were treatment successes. Mean serum glucose, fructosamine and β-hydroxybutyrate concentrations decreased, and investigator assessments of neurological status, musculature and hair coat improved; owner evaluations of cat and owner quality of life were favourable. Common adverse events included emesis, diarrhea, anorexia, lethargy and dehydration. Eight cats had serious adverse events, three of which led to death or euthanasia. The most important adverse event was euglycemic diabetic ketoacidosis, diagnosed in 3 cats and presumed present in a fourth.

Watch out: Historically controlled and open-label — there is no concurrent insulin group in this record, so the 84.0% success figure has no randomised comparator beside it, and the velagliflozin randomised trial cannot be borrowed as bexagliflozin's control. Euglycaemic ketoacidosis affected 3 diagnosed plus 1 presumed cat out of 84 (about 4–5%), and three cats died or were euthanised among the eight with serious adverse events (the record does not attribute each death to ketoacidosis).

Hadd MJ, Bienhoff SE, Little SE, Geller S, Ogne-Stevenson J, Dupree TJ, Scott-Moncrieff JC. Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus. J Vet Intern Med. 2023;37(3):915-924. PMID: 37148170. Registry ID: none in the record. MeSH: Animals · Cats · Blood Glucose · Cat Diseases · Diabetes Mellitus · Diabetic Ketoacidosis · Fructosamine · Glucose · Hyperglycemia · Hypoglycemic Agents · Pilot Projects · Prospective Studies · Quality of Life · Sodium · Pyrans

Synthesis: SGLT2 inhibition controls feline diabetes about as well as insulin in the one randomised trial — and buys that control with a real ketoacidosis risk

Synthesis

Who: Synthesis of the cards above: Niessen 2024 (randomised, open-label noninferiority field trial of velagliflozin vs Caninsulin, 116 efficacy cats), Behrend 2024 SENSATION (252 cats on velagliflozin alone, baseline-controlled), and Hadd 2023 (84 newly diagnosed cats on bexagliflozin, historically controlled).

Result: The controlled comparison that genuinely exists is Niessen 2024: velagliflozin was noninferior to twice-daily Caninsulin for day-45 treatment success (54% vs 42%) and ahead on several day-91 glycaemic measures, without clinical hypoglycaemia. The two large open-label field studies are consistent with real glycaemic control from either drug as sole therapy (84.0% success for bexagliflozin at day 56; median BG 436 → 125 mg/dL by day 180 for velagliflozin). The cost is consistent too: diabetic ketoacidosis in 4/61 (7%) on velagliflozin vs 0/66 on insulin in the randomised trial, 18/252 (7.1%) in SENSATION — 5.1% in insulin-naïve cats vs 18.4% in previously insulin-treated cats, 77.8% of episodes euglycaemic and most within the first 14 days — and euglycaemic ketoacidosis diagnosed in 3 and presumed in a fourth of Hadd's 84 bexagliflozin cats. Glycaemic control: shown. Ketoacidosis, often euglycaemic and early: also shown, and it is the figure that decides which cats should get these drugs.

Watch out: Only the velagliflozin claim rests on randomisation, and that trial was open label; bexagliflozin's effectiveness figures are uncontrolled. Cats switching from insulin appear at higher ketoacidosis risk than insulin-naïve cats in SENSATION — an observational contrast within one study, not a randomised one.

Synthesis of Niessen SJM et al. (PMID: 38884190), Behrend EN et al. (PMID: 39142336) and Hadd MJ et al. (PMID: 37148170). Registry ID as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.